A proposed FDA rule could significantly reshape the future of direct-to-consumer (DTC) pharmaceutical advertising, prompting life sciences brands to rethink how they reach and engage patients.
In our latest point of view, Dave Leitner, EVP, Head of Media, explores the potential impact of the FDA’s proposal to eliminate the long-standing “adequate provision” standard for broadcast advertising and what it could mean for marketers moving forward.
While the proposal is far from finalized, brands should begin planning now. The POV outlines how the industry is responding, key legal and regulatory considerations, and strategic opportunities to future-proof media investments through digital, connected TV, HCP engagement and disease state education initiatives.
Download the full POV to explore practical recommendations for maintaining brand impact and staying ahead of a rapidly evolving regulatory landscape.
Download the POV
Submit Your Details to Access the Content